We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Webinar Recordings » OTC Regulation - Webinar Recording/Transcript

Other Options

USB Audio Recording/Transcript - March 18, 2019

$287.00

USB Audio Recording/Transcript - March 18, 2019

$258.00

USB Audio Recording/Transcript - March 18, 2019

$244.00

USB Audio Recording/Transcript - March 18, 2019

$230.00

USB Audio Recording/Transcript - March 18, 2019

$215.00

OTC Regulation - Webinar Recording/Transcript

$287.00
Webinar Recordings

Product Details

OTC Regulation: Latest Developments and Best Practices

There’s pending OTC monograph legislation in Congress that could result in significant changes in the OTC space. And, the FDA issued draft guidance on OTC innovation in 2018.

Christine Kirk — an associate in the Food and Drug Group of Arnall Golden Gregory’s healthcare practice — will discuss recent developments in OTC regulation and enforcement as well as key compliance topics. You’ll learn about:

  • Significant OTC monograph reform legislation that is currently pending in Congress (H.R. 269) which would:
    • Establish an OTC user fee program
    • Change the way that monographs are issued
    • Provide a pathway for limited exclusivity for certain OTC products
  • 2018 draft guidance on innovation in the OTC space published as Innovative Approaches for Nonprescription Drug Products which includes:
    • The development of labeling in addition to the DFL
    • The implementation of additional conditions so that consumers appropriately self-select and use the product
  • Recent OTC-related enforcement actions
  • Common areas of confusion — such as marketing claims and labeling requirements
  • Key compliance issues and resources

You’ll come away with a deeper understanding of the recent developments in the OTC area.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing